A pioneer in the development and commercialization of high-performance microelectronic systems for cell-based assays, ACEA Biosciences, Inc. (ACEA) is a privately owned biotechnology company in the development and commercialization of high-performance and cutting edge life science research instrumentation. With facilities int he US and China, ACEA Biosciences, Inc. develops and commercializes microelectronic sensor systems for cell-based assays, drug discovery, and diagnostics. It offers x-CELLigence System that is used in biomedicine, diagnostics, toxicology, and pharmaceutical development; CIM systems for real time detection of cell migration and cell invasion; RTCA Cardio, a cardio instrument for label-free-dual-mode monitoring of cardiomyocyte and cardiotoxicity testing; and RTCA HT instruments. The company also provides RTCA DP Analyzers for E-plates 16 and CIM-plates 16; RTCA MP Station that is located inside a tissue culture incubator and capable of switching wells on any E-plates to the RTCA analyzer for impedance measurement; RTCA SP Station that is located inside a tissue culture incubator and capable of switching any wells on the E-Plate 96 to the RTCA analyzer for impedance measurement; and software to operate xCELLigence systems for instrument setup, control and operation, flexible experiment setups, data acquisition, data display and output, and data analysis. Its products have applications in cell proliferation, cell quality, compound-mediated cytotoxicity, cell-mediated cytotoxicity, cell adhesion and spreading, function monitoring of receptor tyrosine kinase signaling, function monitoring of GPCR signaling, and IgE receptor functions.
